首页|血府逐瘀汤合悬饮汤加减治疗结核性胸膜炎胸膜增厚的疗效

血府逐瘀汤合悬饮汤加减治疗结核性胸膜炎胸膜增厚的疗效

扫码查看
目的 观察血府逐瘀汤合悬饮汤加减对结核性胸膜炎(TP)患者胸膜增厚的临床疗效。方法 回顾性分析2019年2月至2023年1月浙江省绍兴市新昌县人民医院收治的93例TP患者,按治疗方法分为中西医组(47例)和对照组(46例),对照组接受抗结核短程化疗方案(2HRZE/4HR)治疗,中西医组在对照组基础上给予血府逐瘀汤合悬饮汤加减治疗,疗程2个月。比较2组中医证候积分、引流量、胸腔积液吸收时间、胸膜厚度、血清炎症因子水平,评估2组临床疗效及安全性。结果 治疗后2组的中医主证、次证及总分较治疗前均降低,且中西医组低于对照组(t=2。745,P=0。007;t=4。667,P<0。01;t=4。776,P<0。01)。与对照组比较,中西医组胸腔引流量减少(t=11。790,P<0。01),胸腔积液吸收时间缩短(t=2。152,P=0。034)。与治疗前相比,中西医组和对照组胸膜厚度较治疗1个月(t=5。426、9。504,P均<0。01)、治疗2个月(t=3。090,P=0。003;t=7。679,P<0。01)增厚,中西医组和对照组治疗2个月的胸膜厚度较治疗1个月变薄(t=2。480,P=0。015;t=2。260,P=0。026);治疗1、2个月,中西医组胸膜厚度较对照组变薄(t=4。904、5。607,均P<0。01)。治疗后2组的血清γ干扰素(INF-γ)、白细胞介素6(IL-6)水平较治疗前均降低,且中西医组低于对照组(t=12。740、5。251,均P<0。01)。中西医组总有效率为93。6%,较对照组的78。3%高(x2=4。559,P=0。033)。中西医组、对照组不良反应总发生率为25。5%、21。7%,2组比较差异无统计学意义(x2=0。185,P=0。667)。结论 血府逐瘀汤合悬饮汤加减联合抗结核短程化疗方案治疗TP,能有效预防胸膜增厚,促进胸腔积液吸收、抑制炎症反应,且安全性高。
Therapeutic effect of Xuefu Zhuyu and Xuanyin Decoction on pleural thickening in patients with tubercu-lous pleurisy
Objective To observe the effect of Xuefu Zhuyu and Xuanyin Decoction on pleural thickening and therapeutic effect in patients with tuberculous pleurisy(TP).Methods A retrospective analysis was conduct-ed on a total of 93 TP patients admitted to Xinchang County People's Hospital from February 2019 to January 2023.The patients were divided into a traditional Chinese and Western medicine group(n=47)and a control group(n=46)by treatment methods.The control group was treated with anti-tuberculosis short-course chemotherapy regi-men(2HRZE/4HR),while the traditional Chinese and Western medicine group was treated with Xuefu Zhuyu and Xuanyin Decoction in addition to the treatment given to the control group,with a treatment period of two months for both groups.The traditional Chinese medicine(TCM)syndrome scores,drainage volume,pleural effusion ab-sorption time,pleural thickness,and serum inflammatory factor levels were compared between the two groups,and the clinical efficacy and safety of the two groups were evaluated.Results After treatment,the scores of main and secondary symptoms in TCM and the total scores of both groups were lower than those before treatment,and the scores of the traditional Chinese and Western medicine group were lower than those of the control group(t=2.745,P=0.007;t=4.667,P<0.01;t=4.776,P<0.01).Compared with the control group,the traditional Chinese and West-ern medicine group showed a reduction in drainage volume(t=11.790,P<0.0 1)and a shortened time for ascites ab-sorption(t=2.152,P=0.034).The pleural thickness in both the traditional Chinese and Western medicine group and the control group was significantly thicker before treatment compared to 1 month after treatment(t=5.426,9.504,all P<0.01)and 2 months after treatment(t=3.090,P=0.003;t=7.679,P<0.01).Furthermore,the pleural thickness in both groups at 2 months after treatment was significantly thinner than that at 1 month(t=2.480,P=0.015;t=2.260,P=0.026).After 1 month and 2 months of treatment,the pleural thickness in the traditional Chi-nese and Western medicine group was significantly thinner than that in the control group(t=4.904,5.607,all P<0.01).After treatment,the serum levels of interferon-gamma(INF-γ)and interleukin-6(IL-6)in both groups were reduced compared to those before treatment,and the levels in the integrated traditional Chinese and Western medicine group were lower than those in the control group(t=12.740,t=5.251,all P<0.01).The total effective rate in the traditional Chinese and Western medicine group was significantly higher than that in the control group(93.6%vs 78.3%,x2=4.559,P=0.033).The total incidence of adverse reactions in the traditional Chinese and Western medicine group and the control group was 25.5%and 21.7%respectively,and there was no statistically significant difference between the two groups(x2=0.185,P=0.667).Conclusion The combination of Xuefu Zhuyu and Xuanyin Decoction and short-course anti-tuberculosis chemotherapy can effectively prevent pleural thicke ning,promote pleural effusion absorption,inhibit inflammatory response,and has high safety in the treatment of TP.

Pleurisy,tuberculousXue Fu Zhu Yu TangPleuraComparative effectiveness research

陈春芳、虞鲁萍、吴巧燕

展开 >

新昌县人民医院呼吸内科,浙江绍兴 312500

胸膜炎,结核性 血府逐瘀汤 胸膜 疗效比较研究

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(19)